Big fortune, orphan medicine market report in 2014

Source: Xinkangjie 2014-10-31 recently, evaluatepharma released the report on orphan drugs in 2014 It is estimated that the market size of orphan drugs will increase from US $97 billion in 2014 to US $176 billion in 2020, with a compound annual growth rate of 10.5%, which is almost twice the growth rate of market size of prescription drugs (except for generic drugs) Besides generic drugs, orphan drugs will account for 19.1% of the prescription drug market in 2020, the report also points out The median per capita cost of orphan drugs was 19 times that of non orphan drugs In terms of R & D, the R & D cost of orphan drugs is relatively low According to phase III clinical statistics, currently, the R & D cost of orphan drugs is half of that of non orphan drugs, enjoying preferential tax policies in the United States (the following data source: evaluatepharma) global orphan drug sales in 2006-2020 and its proportion (unit: US $100 million); per capita cost of patients in 2010-2014 (US $100 million); top 10 orphan drugs in 2014; top 20 orphan drugs in 2020 (unit: US $100 million)